UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): MARCH 27, 2003
ZONAGEN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-21198 76-0233274
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
2408 TIMBERLOCH PLACE, SUITE B-4
THE WOODLANDS, TEXAS 77380
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)
(281) 719-3400
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)
ITEM 5. OTHER EVENTS
On March 27, 2003, Zonagen, Inc. (the "Company") announced in a press
release that it had terminated the merger agreement dated as of October 30, 2002
between Zonagen, Lavipharm Corp. and certain of Lavipharm Corp.'s stockholders,
effective immediately. The merger agreement had provided that if the merger had
not been completed by February 28, 2003, either party could elect to terminate
the merger agreement, in its sole discretion.
A copy of the Company's press release announcing the termination of the
Merger Agreement is attached hereto as Exhibit 99.1. The press release is
incorporated by reference into this Item 5 and the foregoing description of
press release is qualified in its entirety by reference to all of the attached
exhibits.
ITEM 7. EXHIBITS
Exhibit 99.1 -- Press Release dated March 27, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZONAGEN, INC.
Date: March 28, 2003.
By: /s/ Louis Ploth, Jr.
------------------------------------------
Louis Ploth, Jr.
Vice President, Business Development
and Chief Financial Officer
EXHIBIT INDEX
Exhibit
Number Description
------- ------------
99.1 Press Release dated March 27, 2003.